Boston Scientific Corporation

Boston Scientific Corporation kehittää, valmistaa ja markkinoi lääketieteellisiä laitteita, joita käytetään laajalla interventioalan erikoisalalla. Yhtiön tuoteportfoliota leimaa vähemmän invasiiviset hoidot, jotka auttavat lääkäreitä diagnoosissa ja hoidossa samalla kun perinteisen kirurgian tarve vähenee. Sen tuotteita myydään maailmanlaajuisesti sairaaloille, klinikoille, avohoitoyksiköille ja lääkärin vastaanotoille, ja suuri osa myynnistä on sairaalojen hankintaryhmien ja korvausjärjestelmien vaikutuksen alaisena. Yli 45 vuoden kokemuksella lääketeknologiassa Boston Scientific on rakentanut liiketoimintansa jatkuvan tuotekehityksen, kliinisen näytön ja laajan kaupallisen läsnäolon varaan.

24,8 %

69,0 %

14,4 %

+19,9 %

1.62

1.08

— Boston Scientific Corporation
%
Cardiovascular45% Devices used in interventional cardiology, electrophysiology, and peripheral vascular procedures.
Endoscopy20% Tools and systems used to diagnose and treat gastrointestinal and other conditions through minimally invasive procedures.
Urology and Pelvic Health15% Products for urinary tract, kidney stone, and pelvic floor-related procedures and therapies.
Neuromodulation10% Implantable and related therapies used to manage chronic pain and other neurological conditions.
Oncology and Embolization10% Therapies and devices for cancer treatment, including liver cancer and embolization procedures.

Boston Scientific myy ensisijaisesti terveydenhuollon palveluntarjoajille, jotka suorittavat interventiotoimenpiteitä, mukaan lukien sairaalat,...

  • Hospitals and health systemsprimary

    Buy the core interventional device portfolio for procedure rooms and specialty departments because they need reliable clinical outcomes and broad product availability.

  • Physicians and specialist cliniciansprimary

    Influence product choice in cardiology, endoscopy, urology, and oncology based on ease of use, efficacy, and training support.

  • Outpatient facilities and ambulatory surgery centerssecondary

    Purchase devices for procedures migrating out of inpatient settings, where efficiency and reimbursement economics are critical.

  • Group purchasing organizations and hospital networkssecondary

    Negotiate contracts and pricing across consolidated provider systems, affecting access and average selling prices.

  • International distributorsemerging

    Buy and resell products in selected markets where Boston Scientific does not maintain a direct commercial footprint.

Boston Scientific on globaali yritys, jonka tuotteita markkinoidaan 127 maassa. Yhtiön mukaan suurin osa nettomyynnistä...

  • Operates in 127 countries through direct sales and distributors
  • United States is the largest and most strategically important market
  • Direct sales organizations support most net sales in core markets
  • Distributors are used where direct presence is not economical or strategic
  • China is a competitive hotspot with strong local suppliers
  • Global exposure increases sensitivity to reimbursement and tendering rules

Boston Scientificin strategia keskittyy viiteen määriteltyyn painopisteeseen: vahvistaa kategorian johtajuutta, laajentua...

01
Vahvista kategorian johtajuuttashort-term

Core franchises provide the scale, clinical credibility, and commercial leverage that support repeat purchasing and hospital access.

02
Laajentua korkean kasvun läheisiin kategorioihinmedium-term

Adjacent categories can reuse the company’s sales channels and clinical relationships while broadening growth beyond mature lines.

03
Ajatella globaalia laajentumistamedium-term

International markets increase the addressable customer base and reduce dependence on any single healthcare system.

04
Kehitä keskeisiä kyvykkyyksiälong-term

Digital, regulatory, and operational capabilities are increasingly important in a device market shaped by AI, cybersecurity, and evidence requirements.

Boston Scientific kohtaa kovaa kilpailua kaikilla tuotealueillaan, mukaan lukien paine suurten monialayritysten...

high

Competitive pricing pressure and market share loss

The company competes against large diversified device makers, niche specialists, and low-cost entrants, which can force concessions and reduce average selling prices.

Scope
Core interventional device franchises
Materiality
high
high

Regulatory and reimbursement changes

Approval pathways and payer coverage determine whether new devices can launch and how quickly procedures are adopted.

Scope
U.S., EU, and other major healthcare markets
Materiality
high
high

Litigation and product liability

Medical device companies face claims tied to product performance, compliance, and patient outcomes, which can create legal costs and provisions.

Scope
Global operations and legacy product lines
Materiality
high
high

Cybersecurity and IT/OT disruption

Manufacturing, shipping, and sensitive data systems depend on secure global infrastructure that can be targeted by malicious actors.

Scope
Enterprise systems and connected operations
Materiality
high
medium

China and local-supplier competition

Domestic competitors in China may benefit from local procurement preferences and pricing advantages.

Scope
International sales in China
Materiality
medium
Revenue recognition and deferred revenue
Quarterly comparability and reported net sales
Goodwill and intangible asset impairment
Potential non-cash charges to earnings
Legal and product liability accruals
Earnings volatility and cash outflows
Inventory provisions
Gross margin and operating profit
Non-GAAP adjustments
Adjusted earnings versus GAAP earnings

: 11.8.2026